We recently compiled a list of the 11 Cheap ESG Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands ...

Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

Regeneron has signed a collaboration deal ... with the lead party retaining global development and commercial responsibility. For CNS programs, both companies will have the option at candidate ...

We think the firm does face environmental, social, and governance risks, particularly related to US drug price-related policy changes (roughly 80% of Regeneron's revenue for top-selling drugs ...

At Regeneron, we take this responsibility very seriously and are committed to delivering breakthrough therapies that improve patient lives. To achieve this, companies must be able to compete ...